search
Back to results

An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours

Primary Purpose

Postoperative Pain

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Morphine 6-glucuronide
Morphine
Sponsored by
Paion UK Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postoperative Pain focused on measuring Morphine 6-glucuronide, Morphine, Patient Controlled Analgesia, Post Operative Nausea and Vomiting

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patients undergoing any of the following elective surgical procedures that, in the Investigator's opinion, would have required the use of post-operative patient controlled analgesia for a minimum of 24 hours:
  • Abdominal hysterectomy with the exception of laparoscopic procedures.
  • Bowel / gastrointestinal (GI) surgery
  • Major urological surgery
  • Aged ≥ 18 years
  • American Society of Anesthesiologists (ASA) grades I to III
  • If female, the patient had to be post-menopausal (last menstruation > 1 year previously), or surgically sterile (e.g. full hysterectomy or tubal ligation). If neither of these was the case, she had to use adequate contraception (i.e. hormonal contraceptive, intrauterine device (IUD), or a double barrier method) and to have a negative urine pregnancy test during the 24-hours prior to surgery.
  • Provide written informed consent to participate in the trial prior to surgery.

Exclusion Criteria:

  • The patient was pregnant or lactating.
  • Had a known sensitivity to morphine or other opiates, or a medical condition such that opiates were contraindicated.
  • Had a known sensitivity to paracetamol, or a medical condition such that paracetamol was contraindicated.
  • Had received any investigational drug within the 90 days prior to the start of the study, or was scheduled to receive one during the study period.
  • Had been involved in any previous M6G study.
  • Had a documented history or current evidence of alcohol or drug abuse within the year prior to screening.
  • Had clinically significant findings on pre-treatment evaluations (e.g. laboratory results, electrocardiograms, medical history, physical examination) that, in the Investigator's opinion, should have excluded them from the study.
  • Had a concurrent disorder that resulted in excessive pain that, in the Investigator's opinion, would have interfered with the pain assessments during the study (e.g.severe rheumatoid arthritis, muscle dystrophy or neuropathic pain).
  • Had a blood clotting disorder or other blood dyscrasias.
  • Had requested the use of epidural or intrathecal anaesthesia techniques.
  • Required the use of a local anaesthetic block and/or infiltration of wound sites.
  • Required the concomitant use of opioids or non-steroidal anti-inflammatory drugs(NSAIDs) during the study due to an existing concurrent condition.
  • Had a history of Left Ventricular Failure or compromised cardiovascular function, defined as New York Heart Association (NYHA) level 3.
  • Had a history of severe renal impairment or a creatinine level > 3 times the upper limit of normal.
  • Was having surgery that would have prevented the use of oral or rectal paracetamol(iv administration of paracetamol was not allowed).
  • Was expected to require prolonged ventilation after surgery.
  • Was opioid tolerant or had a history of chronic opioid use.
  • Had cognitive impairment that would, in the Investigator's opinion, have precluded participation or compliance with protocol defined procedures (i.e. use of PCA).

Sites / Locations

  • Teaching Hospital Bulovka, Department of Urology
  • Anaesthetisia - Resuscitation Department, Tenon Hospital
  • Universitätsklinikum Bonn, Klinik und Poliklinik f. Anaesthesiologie
  • Department of Anaesthesiology, Leiden University Medical Centre
  • Ii Klinika Anestezjologii i It
  • Intensive Care Unit, Level 5, Western Infirmary,
  • St John's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

M6G

Morphine

Arm Description

An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.

An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.

Outcomes

Primary Outcome Measures

Incidence and severity of nausea
To compare the incidence and severity of nausea in the study treatment groups, during the 18-hour period starting 6 hours after titration to pain relief; following confirmation of the assumption of non-inferiority between the two groups of pain relief over the 24-hour post-operative period. Pain relief and nausea were determined by measuring the areas under the curves of pain intensity and nausea verbal rating scale scores.

Secondary Outcome Measures

Analgesic effect
To compare the analgesic effect of the study treatments using an Investigator- and patient-administered VRS-11 scale of pain intensity over the following time periods following achievement of baseline pain relief. 0-12 hours (AUCbaseline-12) 0-48 hours (AUCbaseline - 48) 12-24 hours (AUC12 - 24) 24-48 hours (AUC24 - 48) Pain levels will be compared using the AUC from baseline.
The incidence and severity of nausea
To compare the incidence and severity of nausea in the study treatment groups over the following time periods following achievement of baseline pain relief: 0-12 hours, 0-24 hours, 0-48 hours, 12-24 hours, 24-48 hours.
The incidence and severity of vomiting
To compare the incidence and severity of vomiting in the study treatment groups over the following time periods following achievement of baseline pain relief: 0-12 hours, 0-24 hours, 0-48 hours, 12-24 hours, 24-48 hours
The amounts of study drug required to achieve a baseline pain severity score of ≤ 3
To compare the amounts of study drug required to achieve a baseline pain severity score of ≤ 3

Full Information

First Posted
March 5, 2010
Last Updated
August 28, 2023
Sponsor
Paion UK Ltd.
Collaborators
Chiltern International Ltd., HFL Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT01082471
Brief Title
An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours
Official Title
A Randomised Double-blind Study to Compare the Analgesic Efficacy and Safety Profiles of M6G and Morphine, as a Loading Dose Followed by PCA, in Patients Suffering Moderate to Severe Post-operative Pain Requiring PCA for at Least 24 Hours
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
November 2005 (undefined)
Primary Completion Date
November 2006 (Actual)
Study Completion Date
December 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Paion UK Ltd.
Collaborators
Chiltern International Ltd., HFL Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To compare the incidence and severity of nausea in the study treatment groups, during the 18-hour period starting 6 hours after titration to pain relief; following confirmation of the assumption of non-inferiority between the two groups of pain relief over the 24 hour post-operative period. Pain relief and nausea will be determined by measuring the areas under the curves of pain intensity and nausea verbal rating scale scores.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
Morphine 6-glucuronide, Morphine, Patient Controlled Analgesia, Post Operative Nausea and Vomiting

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
517 (Actual)

8. Arms, Groups, and Interventions

Arm Title
M6G
Arm Type
Experimental
Arm Description
An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
Arm Title
Morphine
Arm Type
Active Comparator
Arm Description
An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
Intervention Type
Drug
Intervention Name(s)
Morphine 6-glucuronide
Intervention Type
Drug
Intervention Name(s)
Morphine
Primary Outcome Measure Information:
Title
Incidence and severity of nausea
Description
To compare the incidence and severity of nausea in the study treatment groups, during the 18-hour period starting 6 hours after titration to pain relief; following confirmation of the assumption of non-inferiority between the two groups of pain relief over the 24-hour post-operative period. Pain relief and nausea were determined by measuring the areas under the curves of pain intensity and nausea verbal rating scale scores.
Time Frame
The 6-18 hour period after titration to pain relief
Secondary Outcome Measure Information:
Title
Analgesic effect
Description
To compare the analgesic effect of the study treatments using an Investigator- and patient-administered VRS-11 scale of pain intensity over the following time periods following achievement of baseline pain relief. 0-12 hours (AUCbaseline-12) 0-48 hours (AUCbaseline - 48) 12-24 hours (AUC12 - 24) 24-48 hours (AUC24 - 48) Pain levels will be compared using the AUC from baseline.
Time Frame
0-48 hours after titration to pain relief
Title
The incidence and severity of nausea
Description
To compare the incidence and severity of nausea in the study treatment groups over the following time periods following achievement of baseline pain relief: 0-12 hours, 0-24 hours, 0-48 hours, 12-24 hours, 24-48 hours.
Time Frame
0-48 hours
Title
The incidence and severity of vomiting
Description
To compare the incidence and severity of vomiting in the study treatment groups over the following time periods following achievement of baseline pain relief: 0-12 hours, 0-24 hours, 0-48 hours, 12-24 hours, 24-48 hours
Time Frame
0-48 hours
Title
The amounts of study drug required to achieve a baseline pain severity score of ≤ 3
Description
To compare the amounts of study drug required to achieve a baseline pain severity score of ≤ 3
Time Frame
60-30mins before close of surgery to time 0.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients undergoing any of the following elective surgical procedures that, in the Investigator's opinion, would have required the use of post-operative patient controlled analgesia for a minimum of 24 hours: Abdominal hysterectomy with the exception of laparoscopic procedures. Bowel / gastrointestinal (GI) surgery Major urological surgery Aged ≥ 18 years American Society of Anesthesiologists (ASA) grades I to III If female, the patient had to be post-menopausal (last menstruation > 1 year previously), or surgically sterile (e.g. full hysterectomy or tubal ligation). If neither of these was the case, she had to use adequate contraception (i.e. hormonal contraceptive, intrauterine device (IUD), or a double barrier method) and to have a negative urine pregnancy test during the 24-hours prior to surgery. Provide written informed consent to participate in the trial prior to surgery. Exclusion Criteria: The patient was pregnant or lactating. Had a known sensitivity to morphine or other opiates, or a medical condition such that opiates were contraindicated. Had a known sensitivity to paracetamol, or a medical condition such that paracetamol was contraindicated. Had received any investigational drug within the 90 days prior to the start of the study, or was scheduled to receive one during the study period. Had been involved in any previous M6G study. Had a documented history or current evidence of alcohol or drug abuse within the year prior to screening. Had clinically significant findings on pre-treatment evaluations (e.g. laboratory results, electrocardiograms, medical history, physical examination) that, in the Investigator's opinion, should have excluded them from the study. Had a concurrent disorder that resulted in excessive pain that, in the Investigator's opinion, would have interfered with the pain assessments during the study (e.g.severe rheumatoid arthritis, muscle dystrophy or neuropathic pain). Had a blood clotting disorder or other blood dyscrasias. Had requested the use of epidural or intrathecal anaesthesia techniques. Required the use of a local anaesthetic block and/or infiltration of wound sites. Required the concomitant use of opioids or non-steroidal anti-inflammatory drugs(NSAIDs) during the study due to an existing concurrent condition. Had a history of Left Ventricular Failure or compromised cardiovascular function, defined as New York Heart Association (NYHA) level 3. Had a history of severe renal impairment or a creatinine level > 3 times the upper limit of normal. Was having surgery that would have prevented the use of oral or rectal paracetamol(iv administration of paracetamol was not allowed). Was expected to require prolonged ventilation after surgery. Was opioid tolerant or had a history of chronic opioid use. Had cognitive impairment that would, in the Investigator's opinion, have precluded participation or compliance with protocol defined procedures (i.e. use of PCA).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexander Binning, M.D.
Organizational Affiliation
Intensive Care Unit, Level 5, Western Infirmary, Glasgow, G11 6NT
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
James Lees, B.Sc.
Organizational Affiliation
Paion UK Ltd.
Official's Role
Study Director
Facility Information:
Facility Name
Teaching Hospital Bulovka, Department of Urology
City
Prague
ZIP/Postal Code
180 00
Country
Czechia
Facility Name
Anaesthetisia - Resuscitation Department, Tenon Hospital
City
Paris
State/Province
Cedex 20
ZIP/Postal Code
75970
Country
France
Facility Name
Universitätsklinikum Bonn, Klinik und Poliklinik f. Anaesthesiologie
City
Bonn
ZIP/Postal Code
53105
Country
Germany
Facility Name
Department of Anaesthesiology, Leiden University Medical Centre
City
Leiden
ZIP/Postal Code
2300 RC
Country
Netherlands
Facility Name
Ii Klinika Anestezjologii i It
City
Lublin
ZIP/Postal Code
20-081
Country
Poland
Facility Name
Intensive Care Unit, Level 5, Western Infirmary,
City
Glasgow
State/Province
Renfrewshire
ZIP/Postal Code
G11 6NT
Country
United Kingdom
Facility Name
St John's Hospital
City
Livingston
State/Province
West Lothian
ZIP/Postal Code
EH54 6PP
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours

We'll reach out to this number within 24 hrs